Latest Tumor antigen Stories
Abstract # 2693 ORLANDO, Fla., April 4, 2011 /PRNewswire-USNewswire/ -- Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 102nd Annual Meeting 2011 showing that when tumor cryoablation - or the freezing of tumor tissue while preserving tumor-associated antigens - is coupled with immune system modulation, the procedures have the potential to initiate or amplify tumor immunity. (Logo:...
The immune system is capable of recognizing tumor growth, and naturally mounts an anti-cancer defense.
CAMBRIDGE, Mass., Feb.
GAITHERSBURG, Md., Aug.
Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma.
EPFL study reveals importance of relation between the lymphatic system and tumors.
DES PLAINES, Ill., March 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK. GSK's MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) candidate is currently being evaluated as an adjuvant treatment in melanoma biopsy specimens in the Phase III clinical study...
The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment.
A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal Immunity.
It was once thought that the two communities of cells within a cancerous breast tumor â€“ fast-growing malignant cells and the normal cells that surround them â€“ existed independently, without interaction.
- To fire mitraille at.